Business
Net Asset Value & Factsheet - 31 December 2019
Net Asset Value & Factsheet - 31 December 2019.
About this update from Aquila European Renewables Plc Registered
[{"type":"text","content":"\n \nRNS Number : 6539C Aquila European Renewables Income 11 February 2020 \n\n11 February 2020\nThis announcement contains inside information for the purpose of Article 7 of the Market Abuse Regulation (EU) No 596/2014. \n \nAquila European Renewables Income Fund plc\n \nNet Asset Value and Factsheet - 31 December 2019\n \n \nAquila European Renewables Income Fund plc (the Company), a Euro income fund, announces its un-audited net asset value (\"NAV\") as at 31 December 2019, on a cum-income basis, was EUR 158,916,758 or 102.75 cents per ordinary share. \n \nFurther details will shortly be available in the quarterly factsheet section of the Company's website at: https://www.aquila-european-renewables-income-fund.com.\n \nFor further details contact:\n \nMedia contacts:\n\nSmithfield Consultants\nGed Brumby | 020 3047 2527\nJohn Kiely class=\"l\">Vicki Paine\n \nNOTES\nAquila European Renewables Income Fund (\"AERIF\" or the \"Company\") is a recently established, London-listed renewable energy infrastructure investment company with the aim to provide investors with an attractive long-term, income-based return in EUR through a diversified portfolio of hydropower, onshore wind and solar PV investments across continental Europe and Ireland. Through the diversification of generation technologies, the seasonal production patterns of these asset types complete each other to balance the cash flow, while the geographic diversification serves to reduce exposure to one single energy market. AERIF is targeting an aggregate annual yield of 5.0% once fully invested.\n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END MSCLFLFFBLLLBBV\n ","length":2884,"tagName":"div"}]